Nucleic acid amplification testing of blood donors for transfusion- transmitted infectious diseases

Transfusion

Volumn 40, Issue 2, 2000, Pages 143-159

  Busch, M P ^a   Kleinman, S H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID;

BLOOD DONOR; DISEASE TRANSMISSION; GENE AMPLIFICATION; HEPATITIS C VIRUS; HOSPITAL INFECTION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFECTION RISK; LABORATORY TEST; MASS SCREENING; NEEDLESTICK INJURY; POLYMERASE CHAIN REACTION; REVIEW; TISSUE INJURY; VIREMIA; VIRUS REPLICATION; VIRUS TRANSMISSION; ARTICLE; BLOOD TRANSFUSION; COMMUNICABLE DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BLOOD DONORS; BLOOD TRANSFUSION; COMMUNICABLE DISEASES; GENE AMPLIFICATION; HEPATITIS C; HIV INFECTIONS; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0034133532     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40020143.x     Document Type: Review

References (39)

1. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997;127:904-9.
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The NHLBI Retrovirus Epidemiology Blood Donor Study. N Engl J Med 1996;334:1685-90.
3. DeOliveira CF, Diaz RS, Machado DM, et al. Surveillance of HIV-1 genetic subtypes and diversity in the US blood supply. Transfusion (in press).
4. Pau CP, Hu DJ, Spruill C, et al. Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion 1996;36:398-400.
5. Imagawa DT, Lee MH, Wolinsky SM, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989;320:1458-62.
6. Farzadegan H, Polis MA, Wolinsky SM, et al. Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1988;108:785-90.
7. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-905.
8. Imagawa D, Detels R. HIV-1 in seronegative homosexual men (letter). N Engl J Med 1991;325:1250-1.
9. Roy MJ, Damato JJ, Burke DS. Absence of true serorever-sion of HIV-1 antibody in seroreactive individuals. JAMA 1993;269:2876-9.
10. Lifson AR, Stanley M, Pane J, et al. Detection of human immunodeficiency virus DNA using the polymerase chain reaction in a well-characterized group of homosexual and bisexual men. J Infect Dis 1990;161:436-9.
11. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999;353:359-63.
12. Busch MP, Watanabe KK, Smith JW, et al. False-negative testing errors in routine virus marker screening of blood donors. The Retrovirus Epidemiology Donor Study. Transfusion (in press).
13. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997;102:117-24; discussion 125-6.
14. Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994;34:283-9.
15. Busch MP, Lee LLL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion; implications for screening of blood and tissue donors. Transfusion 1995;35:91-7.
16. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993;168:1490-501.
17. Beach MJ, Meeks EL, Mimms LT, et al. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees. J Med Virol 1992;36:226-37.
18. Farci P, London WT, Wong DC, et al. The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia. J Infect Dis 1992;165:1006-11.
19. Murthy KK, Henrard DR, Eichberg JW, et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999;39:688-93.
20. Busch MP, Satten GA, Herman SA, et al. Time course and kinetics of HIV viremia during primary infection (abstract). Transfusion 1996;36(Suppl):41S.
21. Busch MP, Satten GA, Sakahara NS, et al. Time course and dynamics of viremia during early stages of HIV seroconversion (abstract) . Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997:203.
22. Stramer SL, Porter RA, Brodsky JP, et al. Sensitivity of HIV and HCV RNA detection by pooled genome amplification testing (GAT) (abstract). Transfusion 1998;38(Suppl):70S.
23. Busch MP, Rawal BD, Feibig EW, et al. Dynamics of HCV viremia and seroconversion in transfusion-acquired HCV infections (abstract). Transfusion 1998;38(Suppl):72S.
24. Ulrich PP, Romeo JM, Lane PK, et al. Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest 1990;86:1609-14.
25. Mimms LT, Mosley JW, Hollinger FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. Br Med J 1993;307:1095-7.
26. Rawal BD, Kleinman SH, Kuhns MC, Busch MP. Infectious HBV window period and its projected reduction by genome amplification testing (abstract). Transfusion 1998;38(Suppl):91S.
27. Kuhns MC, McNamara AL, Peterson B, et al. Detection of hepatitis B seroconversion by highly sensitive assays for surface antigen and HBV DNA (abstract). Transfusion 1998;38(Suppl):91S.
28. Schuurman R, Descamps D, Weverling GJ, et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996;34:3016-22.
29. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 1996;34:2695-701.
30. Brodine SK, Mascola JR, Weiss PJ, et al. Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995;346:1198-9.
31. Fransen K, Buve A, Nkengasong JN, et al. Longstanding presence in Belgians of multiple non-B HIV-1 subtypes (letter). Lancet 1996;347:1403.
32. Alaeus A, Lidman K, Sonnerborg A, Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997;11:859-65.
33. Triques K, Coste J, Perret JL, et al. Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol 1999;37:110-6.
34. Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1,2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997;35:187-92.
35. Holodniy M, Mole L, Yen-Lieberman B, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAlNER PPT, and standard VACUTAINER tubes. J Clin Microbiol 1995;33:1562-6.
36. Vandamme AM, Schmit JC, Van Dooren S, et al. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:127-39.
37. Plasma-derived medicinal products: the introduction of genomic amplification technology (GAT) for the detection of hepatitis C virus RNA in plasma pools. Committee for Proprietary Medicinal Products. CPMP/BWP/390/97. London: European Agency for Evaluation of Medical Products, Oct 22, 1997.
38. Dodd RY, Griffin GD, Conrad A, et al. Pilot study to determine the feasibility of PCR testing of pooled donor samples for HBV, HCV, HAV, and parvovirus B19 (abstract). Transfusion 1977;37(Suppl):15S.
39. Hewlett IK, Epstein JS. Food and Drug Administration Conference on the Feasibility of Genetic Technology to Close the HIV Window in Donor Screening. Transfusion 1997;37:346-51.